Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Case Reports in Gastrointestinal Medicine, enter your email address in the box below.

Case Reports in Gastrointestinal Medicine
Volume 2012 (2012), Article ID 395801, 6 pages
http://dx.doi.org/10.1155/2012/395801
Case Report

Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia

Hiroko Sugimoto-Sekiguchi,1 Haruko Tashiro,1 Ryosuke Shirasaki,1 Tomio Arai,2,3 Tadashi Yamamoto,1 Yoko Oka,1 Nobu Akiyama,1 Kazuo Kawasugi,1 and Naoki Shirafuji1

1Department of Hematology/Oncology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan
2Division of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan
3Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan

Received 8 July 2012; Accepted 28 August 2012

Academic Editors: E. Altintas and S. Chokhavatia

Copyright © 2012 Hiroko Sugimoto-Sekiguchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. J. Van Esser, B. Van Der Holt, E. Meijer et al., “Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT,” Blood, vol. 98, no. 4, pp. 972–978, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Shaffer, C. M. Rooney, and S. Gottschalk, “Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation,” Immunotherapy, vol. 2, no. 5, pp. 663–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Meijer and J. J. Cornelissen, “Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients,” Current Opinion in Hematology, vol. 15, no. 6, pp. 576–585, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bacigalupo, “Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects,” Bone Marrow Transplantation, vol. 35, no. 3, pp. 225–231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Cohen, M. Gandhi, P. Naik et al., “Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning,” British Journal of Haematology, vol. 129, no. 2, pp. 229–239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Rosenfeld, D. Follmann, O. Nunez, and N. S. Young, “Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome,” Journal of the American Medical Association, vol. 289, no. 9, pp. 1130–1135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Calistri, M. Tiribelli, M. Battista et al., “Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia,” American Journal of Hematology, vol. 81, no. 5, pp. 355–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Raghavachar, A. Ganser, M. Freund, H. Heimpel, F. Herrmann, and H. Schrezenmeier, “Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia,” Cytokines and Molecular Therapy, vol. 2, no. 2, pp. 215–223, 1996. View at Google Scholar · View at Scopus
  9. G. M. Viola, Y. Zu, K. R. Baker, and S. Aslam, “Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy,” Medical Oncology, pp. 1–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Wondergem, S. J. C. Stevens, J. J. W. M. Janssen et al., “Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression,” Blood, vol. 111, no. 3, p. 1739, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C. W. Marsh, S. E. Ball, J. Cavenagh et al., “Guidelines for the diagnosis and management of aplastic anaemia,” British Journal of Haematology, vol. 147, no. 1, pp. 43–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Dorr, G. Doolittle, and J. Woodroof, “First report of a B cell lymphoproliterative disorder arising in a patient treated with immune suppressants for severe aplastic anemia,” American Journal of Hematology, vol. 52, no. 2, pp. 108–113, 1996. View at Google Scholar · View at Scopus
  13. Y. Suzuki, N. Niitsu, M. Hayama et al., “Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review,” Acta Haematologica, vol. 121, no. 1, pp. 21–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Scheinberg, S. H. Fischer, L. Li et al., “Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia,” Blood, vol. 109, no. 8, pp. 3219–3224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Scheinberg, O. Nunez, B. Weinstein et al., “Horse versus rabbit antithymocyte globulin in acquired aplastic anemia,” New England Journal of Medicine, vol. 365, no. 5, pp. 430–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. G. Afable II, M. Shaik, Y. Sugimoto et al., “Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia,” Haematologica, vol. 96, no. 9, pp. 1269–1275, 2011. View at Publisher · View at Google Scholar
  17. E. Di Bona, F. Rodeghiero, B. Bruno et al., “Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO),” British Journal of Haematology, vol. 102, no. 2, pp. 330–334, 1999. View at Google Scholar · View at Scopus
  18. R. Garg, S. Faderl, G. Garcia-Manero et al., “Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome,” Leukemia, vol. 23, no. 7, pp. 1297–1302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Peres, S. Savasan, J. Klein, M. Abidi, R. Dansey, and E. Abella, “High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens,” Journal of Clinical Microbiology, vol. 43, no. 7, pp. 3540–3543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Wakabayashi, K. Ohashi, R. Hanajiri et al., “Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring,” Internal Medicine, vol. 49, no. 10, pp. 931–935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. McGuirk, S. Seropian, G. Howe, B. Smith, L. Stoddart, and D. L. Cooper, “Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation,” Bone Marrow Transplantation, vol. 24, no. 11, pp. 1253–1258, 1999. View at Google Scholar · View at Scopus